巴氯芬在帕金森病中的应用。
Baclofen in Parkinson's disease.
作者信息
Lees A J, Shaw K M, Stern G M
出版信息
J Neurol Neurosurg Psychiatry. 1978 Aug;41(8):707-8. doi: 10.1136/jnnp.41.8.707.
Abstract
In a controlled trial, baclofen (mean dose 45 mg daily) signficantly increased disability from Parkinsonism in 12 patients with the long-term levodopa syndrome. Peak dose choreoathetosis was not improved but benefit was observed in all four patients with "off period dystonia." Adverse side effects were common and severe, and included visual hallucinations, vomiting, and dizziness.
摘要
在一项对照试验中，巴氯芬（平均每日剂量45毫克）显著增加了12例长期左旋多巴综合征患者帕金森病导致的残疾程度。峰值剂量的舞蹈手足徐动症未得到改善，但在所有4例“关期肌张力障碍”患者中观察到了益处。不良副作用常见且严重，包括视幻觉、呕吐和头晕。
相似文献
1
Baclofen in Parkinson's disease.巴氯芬在帕金森病中的应用。
J Neurol Neurosurg Psychiatry. 1978 Aug;41(8):707-8. doi: 10.1136/jnnp.41.8.707.
2
Effect of baclofen on tardive dyskinesia.巴氯芬对迟发性运动障碍的影响。
Psychopharmacology (Berl). 1978 Mar 1;56(2):145-51. doi: 10.1007/BF00431840.
3
The relationship between parkinsonism and tardive dyskinesia.帕金森症与迟发性运动障碍之间的关系。
Am J Psychiatry. 1977 Jul;134(7):781-4. doi: 10.1176/ajp.134.7.781.
4
Sodium valproate in the treatment of levodopa-induced dyskinesia.丙戊酸钠治疗左旋多巴诱发的运动障碍。
J Neurol Neurosurg Psychiatry. 1978 Aug;41(8):702-6. doi: 10.1136/jnnp.41.8.702.
5
Baclofen in the treatment of tardive dyskinesia.巴氯芬治疗迟发性运动障碍
Am J Psychiatry. 1978 Dec;135(12):1562-3. doi: 10.1176/ajp.135.12.1562.
6
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.新型 mGluR5 负变构调节剂 Dipraglurant 治疗帕金森病左旋多巴诱导运动障碍的 2A 期临床试验。
Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.
7
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).金刚烷胺缓释剂治疗帕金森病左旋多巴诱导的异动症（EASED研究）。
Mov Disord. 2015 May;30(6):788-95. doi: 10.1002/mds.26159. Epub 2015 Feb 4.
8
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.长效多巴胺受体激动剂卡麦角林用于早期帕金森病：一项为期5年的双盲、左旋多巴对照研究的最终结果
CNS Drugs. 2004;18(11):733-46. doi: 10.2165/00023210-200418110-00003.
9
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.AFQ056 在伴有左旋多巴诱导运动障碍的帕金森病患者中的 13 周、随机、剂量发现研究。
Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561. Epub 2013 Jul 12.
10
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.依托必利可对抗帕金森病中左旋多巴诱导的运动障碍：一项剂量探索研究。
Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.
引用本文的文献
1
Treatment of dystonia and tics.肌张力障碍和抽动的治疗。
Clin Park Relat Disord. 2019 Dec 4;2:12-19. doi: 10.1016/j.prdoa.2019.11.005. eCollection 2020.
2
Parkinson's disease treatment: past, present, and future.帕金森病的治疗：过去、现在和未来。
J Neural Transm (Vienna). 2020 May;127(5):785-791. doi: 10.1007/s00702-020-02167-1. Epub 2020 Mar 14.
3
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective.巴氯芬用于治疗酒精使用障碍：临床实践视角
Front Psychiatry. 2019 Jan 4;9:708. doi: 10.3389/fpsyt.2018.00708. eCollection 2018.
4
Gamma-aminobutyric acid(B) receptor activation suppresses stimulus-evoked burst firing in rat substantia nigra reticulata neurons.γ-氨基丁酸B型受体激活可抑制大鼠黑质网状部神经元的刺激诱发爆发式放电。
Neuroreport. 2012 Jan 4;23(1):40-4. doi: 10.1097/WNR.0b013e32834e4899.
5
Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?帕金森病的药物治疗：超越多巴胺D2/D3受体的前景？
J Neural Transm (Vienna). 2008;115(3):431-41. doi: 10.1007/s00702-007-0852-z. Epub 2008 Feb 4.
6
Pain in Parkinson's Disease.帕金森病中的疼痛
Curr Treat Options Neurol. 2004 May;6(3):191-200. doi: 10.1007/s11940-004-0011-x.
7
CSF and plasma GABA levels in Parkinson's disease.帕金森病患者脑脊液和血浆中γ-氨基丁酸水平
J Neurol Neurosurg Psychiatry. 1982 Mar;45(3):253-6. doi: 10.1136/jnnp.45.3.253.
8
Anti-parkinsonian drugs today.当今的抗帕金森病药物。
Drugs. 1984 Sep;28(3):236-62. doi: 10.2165/00003495-198428030-00002.
9
Tiapride in levodopa-induced involuntary movements.硫必利治疗左旋多巴诱发的不自主运动。
J Neurol Neurosurg Psychiatry. 1979 Apr;42(4):380-3. doi: 10.1136/jnnp.42.4.380.
10
Aetiology and natural history of Parkinson's disease.帕金森病的病因及自然史。
Br Med J. 1978 Dec 16;2(6153):1664-6. doi: 10.1136/bmj.2.6153.1664-a.
本文引用的文献
1
The action of beta-phenyl-GABA derivatives on neurones of the cat cerebral cortex.β-苯基-GABA衍生物对猫大脑皮质神经元的作用。
Brain Res. 1974 Apr 26;70(3):501-5. doi: 10.1016/0006-8993(74)90258-3.
2
Letter: G.A.B.A. and Huntington's chorea.信件：γ-氨基丁酸与亨廷顿舞蹈病
Lancet. 1973 Dec 29;2(7844):1499-500. doi: 10.1016/s0140-6736(73)92765-7.
3
4
The action of baclofen on neurons of the substantia nigra and of the ventral tegmental area.巴氯芬对黑质和腹侧被盖区神经元的作用。
Brain Res. 1977 Oct 14;134(3):577-80. doi: 10.1016/0006-8993(77)90834-4.
5
The relationship between parkinsonism and tardive dyskinesia.帕金森症与迟发性运动障碍之间的关系。
Am J Psychiatry. 1977 Jul;134(7):781-4. doi: 10.1176/ajp.134.7.781.
6
Effect of baclofen on cerebrospinal-fluid levels of 5-hydroxyindoleacetic acid and homovanillic acid.巴氯芬对脑脊液中5-羟吲哚乙酸和高香草酸水平的影响。
N Engl J Med. 1977 Feb 24;296(8):452-3. doi: 10.1056/nejm197702242960816.
7
Baclofen (Lioresal) in the treatment ofneuroleptic-induced tardive dyskinesia.巴氯芬（力奥来素）治疗抗精神病药所致迟发性运动障碍。
Acta Psychiatr Scand. 1976 Jul;54(1):17-24. doi: 10.1111/j.1600-0447.1976.tb00090.x.
8
Biochemical effects of baclofen (beta-parachlorophenyl-GABA) on the dopamine and the noradrenaline in the rat brain.巴氯芬（β-对氯苯基-GABA）对大鼠脑内多巴胺和去甲肾上腺素的生化作用。
Acta Pharmacol Toxicol (Copenh). 1977 Feb;40(2):310-20. doi: 10.1111/j.1600-0773.1977.tb02083.x.
9
Baclofen treatment in chronic schizophrenia: a clinical trial.巴氯芬治疗慢性精神分裂症：一项临床试验。
Am J Psychiatry. 1977 Mar;134(3):318-20. doi: 10.1176/ajp.134.3.318.
10
"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease.左旋多巴治疗的帕金森病患者的“关期”肌张力障碍和“开期”舞蹈手足徐动症。
Lancet. 1977 Nov 12;2(8046):1034. doi: 10.1016/s0140-6736(77)92939-7.
Zotero 插件